LLY - Eli Lilly to Pause Enrollment in Most Drug Trials
Pharmaceutical giant Eli Lilly (NYSE: LLY) has been doing its part in the battle against COVID-19. It teamed up with the Indiana State Department of Health to make more testing for the disease available to people in its home state, and plans to start offering drive-thru testing for COVID-19 to active healthcare workers there. But in light of the threat the novel coronavirus poses, and the need for people to reduce human contact to slow its spread, the company is now making a significant change to its clinical trial activities.
While Eli Lilly will continue conducting clinical trials with patients who are already enrolled in them, it will no longer enroll new patients for its ongoing studies, and will also postpone the start of new ones.
Image Source: Getty Images.